Drug Channel Updates
Timely updates on drug shortages, launches, recalls, and more.
Top shortages
Methylpred 4mg 21uu Dpsk
Azelastine Hcl 137mcg 30ml
Rufinamide 40 mcg/ml Oral
Sulfasalazine Dr 500mg 100s
Cetirizine Hcl 1mg/ml 120ml
Acetylcysteine 10% 3x30ml
Senna 8.6mg 100 Vlax Gnil
Aspirin 81mg 120s
Peg 3350/lyt 4000ml
Ketorolac 0.5% 5ml Opth
Drug Launches
Recent Launches
Nicomide (nicotinamide) launched on April 26 and is less than a $5 million market.
Upcoming Launches
Vascepa (icosapent ethyl) is a $847 million market and launched November 5.
Hysingia ER (hydrocodone bitartrate) is a $75 million market and launched March 2.
Chantix (varenicline tartrate) is a$1.2 billion market and was expected to launch November of last year.
Absorica (isotretinoin) is a $203 million market and is expected to launch this week.
Banzel Tablets (ruminamide) is a $302 million market, and the expected launch date is late this month.
Performist (formoterol fumarate) is a $367 million market and is expected to launch mid- to late-June.
Recalls
The most recent recall information with return forms.
Acella Recalls NP Thyroid Tablets
Acella is conducting a voluntary product recall of thirty-five (35) lots of NP THYROID TABLETS. Acella initiated this recall because testing has found these lots to be sub potent. The product contains less than 90% of the labeled amount of Levothyroxine (T4) or Liothyronine (T3).
This recall extends to the Consumer Level, and is only for the lots specified in the notification.
Here’s a full lot list and more information about the recall.
Here’s a return letter to fill out if you ordered the products from PBA Health since March 2020. Any pharmacy with affected product should contact Inmar for a return kit.
